MRK's growing pipeline, acquired assets and new product launches are gaining traction as it builds a diversified growth base ...

Merck and Moderna’s success with a personalized cancer vaccine designed to keep melanoma at bay opens a ​new avenue of ...

Nevertheless, in the past year, Merck (MRK) delivered an impressive 73% return to investors, outpacing the S&P 500. The peak ...

Merck and Moderna’s personalised mRNA cancer vaccine shows promising melanoma results, potentially changing how doctors ...

Moderna has now swung violently in both directions for three straight sessions on the same unchanged clinical news, and the ...

Your resource for the hottest moving stocks and news. We cover all sectors and markets giving everyday investors access to ...

The personalised vaccine has succeeded in a final-stage melanoma trial. Here’s how it works, when it could become available ...

A personalized mRNA therapy met two melanoma trial goals, the FDA cleared the first treatment for GSDIa, and Novo tests lower ...

Moderna and Merck said an experimental cancer vaccine paired with Keytruda helped prevent the recurrence of melanoma in a Phase 3 trial. In 2019, a friend noticed a suspicious mole on Angela Evatt's ...

The vaccine, when combined with the immunotherapy drug Keytruda, reduced skin cancer recurrence and the results were ...

Merck's (MRK) near-term catalysts remain attractive, but execution risks are underestimated at its current valuation following the recent downgrade, RBC Capital Markets said in a ...

Moderna and Merck's experimental cancer vaccine has delivered positive results in a late-stage melanoma trial, giving a major ...